Timothy Smith, MD
Pulmonary Disease · Kansas City, MONPI 1972680627
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $82,174 of the $104,380 with a category attached, or 78.7%. 45 manufacturers reported payments, led by GSK at 31.3% of the total. Reporting peaked in 2019 at $33,248 and has fallen 83.5% since, to $5,491 in 2025. Among pulmonary disease clinicians in MO with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 832 payments — averaging $125.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$33K
- Mylan Specialty L.p.$28K
- AstraZeneca$20K
- Regeneron Healthcare Solutions, Inc.$7K
- Sanofi$3K
- Viatris Specialty LLC$2K
- plus $10K from 39 others
Across 2 payments — averaging $1555.20 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Pfizer$3K
What the payments were for
- Consulting fees$2,6753%
- Speaking & faculty fees$82,17479%
- Travel & lodging$3,7414%
- Food & beverage$15,39815%
- Education$3910%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$104,380 in reported general payments places this provider in the 90th percentile of 295 pulmonary disease providers in Missouri.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 911 | $817,922 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 285 | $204,921 |
| Dupixent SyringeDupilumab | 33 | $177,385 |
| OpsumitMacitentan | 11 | $141,764 |
| Spiriva RespimatTiotropium Bromide | 188 | $137,226 |
| Breo ElliptaFluticasone/Vilanterol | 244 | $130,207 |
| Fasenra PenBenralizumab | 21 | $124,861 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 127 | $100,953 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 200 | $98,505 |
| Dupixent PenDupilumab | 20 | $74,891 |
| NucalaMepolizumab | 12 | $51,363 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 261 | $35,486 |
| Incruse ElliptaUmeclidinium Bromide | 60 | $28,822 |
| Spiriva HandihalerTiotropium Bromide | 39 | $28,203 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 45 | $26,141 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Nucala, Incruse Ellipta | $32,696 | $1,129,9381,441 claims |
| Boehringer IngelheimSpiriva Respimat, Stiolto Respimat, Combivent Respimat | $1,553 | $264,320360 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $20,471 | $223,519332 claims |
| Actelion Pharmaceuticals US, Inc.Opsumit | $410 | $141,76411 claims |
| PfizerEliquis | $22 | $23,91831 claims |
| Teva Pharmaceuticals USA, Inc.Qvar Redihaler | $245 | $6,01615 claims |
| MerckDulera | $190 | $5,93415 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 295 pulmonary disease providers in Missouri.
Other pulmonary disease in Kansas City
- Matthew AboudaraKansas City$30K
- Andrea CoveyKansas City$23K
- Timothy SaetteleKansas City$13K
- James LadesichKansas City$12K
- Andrew BozarthKansas City$11K
- Azzam ParoyaKansas City$10K
- Hamza AlshamiKansas City$10K
- Humam FarahHannibal$840K
- Derek ByersSaint Louis$835K
- Alexander ChenSaint Louis$679K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.